GSK, UCSF Make Deal To Streamline Process for Creating Drugs for Antibiotic-Resistant Bacteria, Cancer and Obesity
GlaxoSmithKline has made a deal with UC-San Francisco to provide early-stage funding for certain academic discoveries that have trouble obtaining traditional grants. The deal aims to streamline the process for translating scientific findings into clinical trials and new drugs. Under the deal, the two organizations will begin three projects related to antibiotic-resistant bacteria, cancer and obesity.
- "Deal Puts Big Pharma, UCSF Researchers Side by Side Targeting Cancer, Obesity and More" (Leuty, "BiotechSF," San Francisco Business Times, 10/19).